BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28623071)

  • 21. Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study.
    Kim SH; Lee DE; Joung JY; Seo HK; Lee KH; Chung J
    Investig Clin Urol; 2020 Mar; 61(2):146-157. PubMed ID: 32158965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
    Iacovelli R; Lanoy E; Albiges L; Escudier B
    BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
    Nouhaud FX; Pfister C; Defortescu G; Giwerc A; Charbit D; Gouerant S; Sabourin JC; Di Fiore F
    Anticancer Drugs; 2015 Sep; 26(8):866-71. PubMed ID: 26020808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.
    Hanna N; Sun M; Meyer CP; Nguyen PL; Pal SK; Chang SL; de Velasco G; Trinh QD; Choueiri TK
    J Clin Oncol; 2016 Sep; 34(27):3267-75. PubMed ID: 27325852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in Japan.
    Miyake H; Harada K; Ozono S; Fujisawa M
    Mol Diagn Ther; 2016 Aug; 20(4):385-92. PubMed ID: 27178184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.
    Kalra S; Atkinson BJ; Matrana MR; Matin SF; Wood CG; Karam JA; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
    BJU Int; 2016 May; 117(5):761-5. PubMed ID: 26032863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
    Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
    World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center.
    Grassi P; Verzoni E; Mariani L; De Braud F; Coppa J; Mazzaferro V; Procopio G
    Clin Genitourin Cancer; 2013 Dec; 11(4):484-8. PubMed ID: 23791435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry.
    Tsimafeyeu I; Shatkovskaya O; Krasny S; Nurgaliev N; Varlamov I; Petkau V; Safina S; Zukov R; Mazhbich M; Statsenko G; Varlamov S; Novikova O; Zaitsev I; Moiseyev P; Rolevich A; Evmenenko A; Popova I; Kaidarova D; Vladimirova L
    Cancer Rep (Hoboken); 2021 Jun; 4(3):e1331. PubMed ID: 33369240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
    Bamias A; Tzannis K; Papatsoris A; Oudard S; Beuselinck B; Escudier B; Liontos M; Elaidi TR; Chrisofos M; Stravodimos K; Anastasiou I; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamia C
    Clin Genitourin Cancer; 2014 Oct; 12(5):373-83. PubMed ID: 24819319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
    Chen YW; Ornstein MC; Wood LS; Allman KD; Martin A; Beach J; Gilligan T; Garcia JA; Rini BI
    Urol Oncol; 2018 Oct; 36(10):470.e19-470.e29. PubMed ID: 30131292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era.
    Macleod LC; Tykodi SS; Holt SK; Wright JL; Lin DW; Tretiakova MS; True LD; Gore JL
    Urology; 2015 Aug; 86(2):262-8. PubMed ID: 26199164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice.
    Kamba T; Yamasaki T; Teramukai S; Shibasaki N; Arakaki R; Sakamoto H; Matsui Y; Okubo K; Yoshimura K; Ogawa O
    Int J Clin Oncol; 2014; 19(3):505-15. PubMed ID: 23813043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy.
    Lee H; Kim YJ; Hwang EC; Kang SH; Hong SH; Chung J; Kwon TG; Kwak C; Kim HH; Oh JJ; Lee SC; Hong SK; Lee SE; Byun SS;
    BMC Cancer; 2017 May; 17(1):364. PubMed ID: 28545466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres.
    Stenman M; Staehler M; Szabados B; Sandström P; Laurell A; Lindskog M; Harmenberg U
    Acta Oncol; 2019 Mar; 58(3):306-312. PubMed ID: 30507262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.
    Kalra S; Verma J; Atkinson BJ; Matin SF; Wood CG; Karam JA; Lin SH; Satcher RL; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
    Clin Genitourin Cancer; 2017 Jun; 15(3):363-370. PubMed ID: 28216278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma.
    Penttilä P; Donskov F; Rautiola J; Peltola K; Laukka M; Bono P
    Eur J Cancer; 2017 Aug; 81():9-16. PubMed ID: 28586749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis.
    Zanwar S; Joshi A; Noronha V; Patil VM; Sable N; Popat P; Menon S; Kothari R; Bhargava P; Kapoor A; Prabhash K
    Indian J Cancer; 2016; 53(4):579-582. PubMed ID: 28485356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era.
    Marchioni M; Bandini M; Pompe RS; Tian Z; Martel T; Kapoor A; Cindolo L; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
    Int Urol Nephrol; 2017 Dec; 49(12):2143-2149. PubMed ID: 28932952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials.
    Molina AM; Lin X; Korytowsky B; Matczak E; Lechuga MJ; Wiltshire R; Motzer RJ
    Eur J Cancer; 2014 Jan; 50(2):351-8. PubMed ID: 24051327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.